A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)

被引：0
|
作者：
Glitza, I. C. [1 ]
Rohlfs, M. L. [1 ]
Iqbal, M. [1 ]
Richard, J. [1 ]
Burton, E. [1 ]
Duncan, S. [1 ]
Brown, C. [1 ]
Anderson, J. [1 ]
Hwu, P. [1 ]
Hwu, W-J. [1 ]
Wong, M. [1 ]
Yee, C. [1 ]
Patel, S. [1 ]
Woodman, S. [1 ]
Amaria, R. [1 ]
Diab, A. [1 ]
Tawbi, H. [1 ]
Davies, M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1301TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.
    Daver, Naval Guastad
    Basu, Sreyashi
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias
    Hendrickson, Stephany
    Brandt, Mark
    Pierce, Sherry
    Gordon, Tauna
    Pemmaraju, Naveen
    Andreeff, Michael
    Ning, Jing
    Kornblau, Steven
    Kadia, Tapan M.
    Dinardo, Courtney Denton
    Konopleva, Marina
    Allison, James Patrick
    Kantarjian, Hagop M.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence
    Zhen, Junjie
    Chen, Linbin
    Wang, Hui
    Li, Dandan
    Lai, Mingyao
    Ding, Ya
    Yang, Yanying
    Li, Jingjing
    Wen, Xizhi
    Cai, Linbo
    Zhang, Xiaoshi
    JOURNAL OF NEURO-ONCOLOGY, 2024, 170 (03) : 665 - 673
  • [23] A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).
    Reiss, Kim Anna
    Mick, Rosemarie
    Teitelbaum, Ursina R.
    O'Hara, Mark H.
    Schneider, Charles John
    Massa, Ryan Campbell
    Karasic, Thomas Benjamin
    Onyiah, Chioma
    Gosselin, Mary Kate
    Donze, Alyssa
    Domchek, Susan M.
    Vonderheide, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase III study (CheckMate 066)
    Long, Georgina V.
    Atkinson, Victoria
    Ascierto, Paolo Antonio
    Robert, Caroline
    Hassel, Jessica Cecile
    Rutkowski, Piotr
    Savage, Kerry J.
    Taylor, Fiona
    Coon, Cheryl
    Gilloteau, Isabelle
    Dastani, Homa
    Waxman, Ian
    Abernethy, Amy Pickar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): results of a phase III study (CheckMate 066)
    Long, G. V.
    Atkinson, V.
    Ascierto, P. A.
    Robert, C.
    Hassel, J. C.
    Rutkowski, P.
    Savage, K. J.
    Taylor, F.
    Coon, C.
    Gilloteau, I.
    Dastani, H. B.
    Waxman, I.
    Abernethy, A. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 27 - 28
  • [26] Intrathecal anti-PD-1 treatment in patients with metastatic melanoma (MM) with leptomeningeal disease (LMD): Real-world data and evidence
    Zhen, Junjie
    Zhang, Xiaoshi
    Cai, Linbo
    Chen, Linbin
    Lai, Mingyao
    Li, Dandan
    Wang, Hui
    Ding, Ya
    Yang, Yanying
    Li, Jingjing
    Wen, Xizhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel)
    Karapetyan, Lilit
    Karunamurthy, Arivarasan
    Cillo, Anthony
    Wang, Shuachao
    Massa, Ryan Campbell
    Rohatgi, Anjali
    Deitrick, Christopher
    Najjar, Yana G.
    Davar, Diwakar
    Luke, Jason J.
    Sander, Cindy
    Rose, Amy
    Rush, Elizabeth
    Joy, Marion
    Kunning, Sheryl
    Bao, Riyue
    Wang, Hong
    Bruno, Tullia C.
    Vignali, Dario
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 68 - 68
  • [29] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 28 - 28
  • [30] A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) plus relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO plus RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma
    Liu, Steven Y.
    Babadjanova, Zulfia
    Oyetunde, Ijeoma
    Gurm, Balmeet
    Jiang, Ruiyun
    Lord-Bessen, Jennifer
    Dixon, Matthew
    Sanchez, Teresa Kong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345